Hot Stuff in the Market – Psychotropic Drugs

Published 1 year ago at 02 Jun 2021

PDF download (GERMAN)

Last year around this time, we have been facing our worst fears - our existence and health have been put on the spot. Since then, Covid-19 has forced us to accept a “new normal” and has led to a big shift in our lives and the entire industry. We had to embrace new technologies and learn how to coexist in the digital world. New businesses worth billions of dollars arose, and one sector in particular has pushed its way to the top - telemedicine.

Telemedicine has become a “safe place” that provides the opportunity of caring for patients remotely when health care providers and patients are unable to meet in person.

Houston, we have a problem.

One year has passed since I have been writing about Teladoc Health Inc and its competitors in the industry. These stocks have surged and the trend still continues.

Covid-19 has forced us to embrace the new digital world and to cope with rising anxiety. Due to the circumstances, one more sector has been seen as a “savior”. The antidepressants market has surged during the Covid outbreak, which affected mental health by elevating anxiety worldwide.

Most people have suffered from a depression episode, anxiety or another disturbed state of mind once in their lifetime. On the one hand, a small “dose” of anxiety can be seen as having a positive impact as it sharpens our awareness.

As traders we are familiar with this feeling when we place our trades and are anxiously waiting whether THE stock will surge or leave us stuck at the bottom.

On the other hand, when the fine line into “excitement” is crossed and it becomes too big to handle, anxiety and mood swings can definitely become our worst enemies.

The antidepressant market

Nobody can deny that the past few years have been especially challenging and many people have been trying different methods to deal with their anxiety. And who understands these struggles better than the big pharmaceutical companies.

The major players in the antidepressants market are already well-known pharma names such as Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, H. Johnson & Johnson, Pfizer Inc., Merck & Co. Inc.

The antidepressant market has definitely become a hot market and one company in particular shows a strong seasonal trend over coming months.

Let me introduce you to Eli Lilly and Company - an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Lilly is currently the largest manufacturer of psychiatric medications and produces Prozac (fluoxetine), Dolophine (methadone), Cymbalta (duloxetine), and Zyprexa.

Seasonal Chart of Eli Lilly & Company over the past 10 years

Seasonal Chart of li Lilly & Company over the past 10 years

Source: Seasonax - by clicking on the chart image you can highlight the above mentioned time period on the chart and take a closer look at a detailed statistical analysis of the pattern

The upcoming increase in demand can be clearly seen on the seasonal chart of Eli Lilly and Company stock. The stock enters a strong seasonal period from mid-June until the end of July. Let us take a closer look at the statistics.

Keep in mind that unlike a standard price chart that simply shows stock prices over a specific time period, a seasonal chart depicts the average price pattern of a stock in the course of a calendar year, calculated over several years. The horizontal axis depicts the time of the year, while the vertical axis shows the level of the seasonal pattern (indexed to 100).

I have highlighted the upcoming strong seasonal phase from June 13 to July 28 calculated over the past 10 years. In this time span of 32 trading days, the shares of Eli Lilly rose on average by a remarkable 6.04 percent. Furthermore, the frequency of positive returns generated over time during this phase indicates that this seasonal pattern is consistent and highly reliable. The bar chart below depicts the return delivered by Eli Lilly in the highlighted time period from June 13 to July 28 in every single year since 2011.

Pattern return for every year since 2011

Pattern returns of li Lilly & Company over the past 10 years

Source: Seasonax - please click on the link to conduct further analysis

This positive upcoming trend applies to the entire Health Care Industry as well.

Looking at the CBOE S&P Healthcare Index and its average monthly performance over the past 10 years, we can discern positive returns in June and July.

CBOE S&P Healthcare Index Average Monthly Returns over the past 10 years

CBOE S&P Healthcare Index Average Monthly Returns over the past 10 years

Source: Seasonax - please click on the link to conduct further analysis

What the Future Holds

Can we claim that the future is bright? Well, for some companies it definitely is. According to the WHO, around 264 million people worldwide suffered from depression in 2020.
To put it in numbers, Mordor Intelligence reported that the global antidepressant market was valued at approximately USD 14,538 million in 2020, and it is expected to garner revenues of USD 17,233 million by 2026, with a CAGR of 2.68% over the forecast horizon.

The numbers undoubtedly suggest that this sector will deliver a strong performance in the future. Moreover, the rising number of cases of mental health disorders is expected to drive the growth of the antidepressant market. However, the right timing and the seasonal behavior of certain stocks will nevertheless determine the success of your investments. Big players such as Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, H. Johnson & Johnson, Pfizer Inc., Merck & Co. Inc. have their own strong seasonal patterns and cycles that can be easily identified.

Timing is Everything!

Apart from the stocks I have presented in this issue of Seasonal Insights, there are numerous other stocks that display recurring seasonal patterns.

To make finding these opportunities even easier, we have launched a Seasonality Screener. The screener is an analytical tool designed to identify trading opportunities with above-average profit potential starting from a specific date. The algorithms behind the screener are based on predictable seasonal patterns that recur almost every calendar year.

Feel free to analyze more than 20.000+ instruments including stocks, (crypto)currencies, commodities, indexes by signing up to a 3-day free trial.

Yours sincerely,
Tea Muratovic
Co-Founder and Managing Partner of Seasonax

This website uses cookies. By continuing to use this website you agree to this. Learn more Accept